Use Xofigo early before your mCRPC* patients with symptomatic bone metastases progress to visceral metastasis
*Metastatic Castration-Resistant Prostate Cancer.
USE XOFIGO IN PATIENTS WHO HAVE:
≥2 bone metastases and no known visceral metastases1
At least 1 symptom associated with mCRPC with bone metastases1
Lymph node involvement up to 3 cm2
Also consider adding Xofigo when referring patients for EBRT
Choose a patient
“I want to fight my cancer, but I also want to know what side effects are related to my treatment.”
- Attorney who travels for business
- Focuses on his professional appearance
- Stays active and enjoys the outdoors
Bill wants a proven treatment with a well-established safety profile.
For Bill, what is your choice for an effective treatment with a well-established safety profile?
“I am prepared to fight, but what about the tolerability of my treatment options?”
- Runs his own accounting firm and is an avid golfer
- Married father of 2 grown children
- Maintains a busy work and social schedule
Fred wants a treatment with both proven efficacy and a well-established safety profile.
For Fred, what is your choice for an effective treatment with a well-established safety profile?
“I want to continue with treatment, but what side effects can I expect from my options?”
- Retired businessman who enjoys playing chess and board games
- Widowed 5 years ago, but has the strong support of his 3 sons and grandchildren
- Enjoys monthly visits with his grandchildren
Effective cancer treatment with a well-established safety profile is important to James.
For James, what is your choice for an effective treatment with a well-established safety profile?
CONSIDER XOFIGO FOR NEWLY DIAGNOSED mCRPC PATIENTS WHO:
- Have been treated with 1 second-generation androgen receptor pathway inhibitor during their treatment journey
ALSO CONSIDER ADDING XOFIGO WHEN REFERRING PATIENTS FOR EBRT
EBRT=External Beam Radiation Therapy.
- Xofigo® (radium Ra 223 dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2019. Return to content
- Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3)(suppl):1-19. Return to content